Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulla Feldt-Rasmussen

Showing results (291-300 of 342) with videos related to

Pageof 35
Sort By:
Molecular and Cellular Endocrinology|March 28, 2006
Characteristics of the Danish families with multiple endocrine neoplasia type 1Anne Charlotte Jäger, Lennart Friis-Hansen, Thomas V O Hansen, et al.
Endocrine Connections|December 15, 2018
Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide studyJes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, et al.
Thyroid Research|April 11, 2023
Hyperthyroidism in pregnancy: design and methodology of a Danish multicenter studyNanna Maria Uldall Torp, Inge Bülow Pedersen, Allan Carlé, et al.
Orphanet Journal of Rare Diseases|March 21, 2026
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension studyMyrl Holida, Aleš Linhart, Nicola Longo, et al.
Clinical Epidemiology|October 24, 2018
Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide studyJes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, et al.
Cancers|April 13, 2023
Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective StudyMagnus Holm, Peter Vestergaard, Morten Møller Poulsen, et al.
Molecular Genetics and Metabolism|January 29, 2023
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry RegistryRobert J Hopkin, Gustavo H Cabrera, John L Jefferies, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2026
Antithyroid drug treatment in pregnancy: A first report from the Danish PRETHYR multicenter studyNanna Maria Uldall-Torp, Inge Bülow Pedersen, Allan Carlé, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|February 28, 2023
Effect of near infrared autofluorescence guided total thyroidectomy on postoperative hypoparathyroidism: a randomized clinical trialEva Lykke, Anders Christensen, Karina Juhl, et al.
Journal of Inherited Metabolic Disease|October 9, 2024
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapiesMyrl Holida, Aleš Linhart, Antonio Pisani, et al.
Pageof 35

Showing results (291-300 of 342) with videos related to

Sort By:
Pageof 35
Molecular and Cellular Endocrinology|March 28, 2006
Characteristics of the Danish families with multiple endocrine neoplasia type 1Anne Charlotte Jäger, Lennart Friis-Hansen, Thomas V O Hansen, et al.
Endocrine Connections|December 15, 2018
Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide studyJes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, et al.
Thyroid Research|April 11, 2023
Hyperthyroidism in pregnancy: design and methodology of a Danish multicenter studyNanna Maria Uldall Torp, Inge Bülow Pedersen, Allan Carlé, et al.
Orphanet Journal of Rare Diseases|March 21, 2026
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension studyMyrl Holida, Aleš Linhart, Nicola Longo, et al.
Clinical Epidemiology|October 24, 2018
Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide studyJes Sloth Mathiesen, Jens Peter Kroustrup, Peter Vestergaard, et al.
Cancers|April 13, 2023
Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective StudyMagnus Holm, Peter Vestergaard, Morten Møller Poulsen, et al.
Molecular Genetics and Metabolism|January 29, 2023
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry RegistryRobert J Hopkin, Gustavo H Cabrera, John L Jefferies, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2026
Antithyroid drug treatment in pregnancy: A first report from the Danish PRETHYR multicenter studyNanna Maria Uldall-Torp, Inge Bülow Pedersen, Allan Carlé, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|February 28, 2023
Effect of near infrared autofluorescence guided total thyroidectomy on postoperative hypoparathyroidism: a randomized clinical trialEva Lykke, Anders Christensen, Karina Juhl, et al.
Journal of Inherited Metabolic Disease|October 9, 2024
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapiesMyrl Holida, Aleš Linhart, Antonio Pisani, et al.
Pageof 35